New unemployment filings in Wisconsin edged higher last week, diverging from a slight national decline and highlighting ongoing labor market fluctuations across states.
The U.S. labor market faced its toughest year since the pandemic in 2025, with layoffs soaring to 1.2 million. Economists warn of an 'uncomfortably slow' rebound in 2026, leaving job seekers navigating a landscape of fierce competition and hiring freezes.
Despite a post-earnings slump and near 52-week lows, Abbott Laboratories' resilient medical device unit, strategic expansion in diabetes care, and a landmark acquisition in cancer diagnostics paint a promising long-term picture for this Dividend Aristocrat.
The long-term agreement, extending to the late 2030s, centers on the joint evolution of ZF's flagship 8-speed automatic transmission for next-generation electrified vehicles, signaling deep collaboration in the auto industry's transition.
Union Pacific is preparing a revised application for its proposed $85 billion merger with Norfolk Southern after regulators rejected the initial filing over competition and information concerns. The deal, which would create the first coast-to-coast freight railroad in the U.S., faces intense scrutiny over its potential impact on shipping costs, labor, and market competition.
As Kevin Warsh emerges as a frontrunner for Federal Reserve Chair, former colleagues paint a picture of a consensus-seeking listener. But with the Fed facing internal divisions and external pressure, questions remain: Is his collaborative style the steady hand needed, or a potential liability in times of crisis?
Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.
GIGABYTE is expanding its strategic partnership with AMD to launch a new generation of AI-enhanced gaming laptops, motherboards, and monitors. This collaboration integrates AMD's Ryzen AI and 3D V-Cache technologies directly into consumer hardware, aiming to deliver tangible benefits in gaming smoothness, system stability, and creative workflow acceleration.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
A video game funded by the British government and designed for schoolchildren has drawn criticism for suggesting that questioning mass migration or researching immigration statistics could lead to referral to the UK's Prevent counter-terrorism programme.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.
The U.S. Air Force Research Laboratory has awarded Palladyne AI a contract for its HANGTIME project, marking a significant expansion of the company's autonomous swarm software from ground and air assets into the space domain. The deal validates the company's core technology but comes as investors weigh its growth potential against ongoing financial challenges.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Marketing technology firm Zeta Global announces a strategic collaboration with OpenAI, aiming to deeply integrate advanced AI into its platform. The move, coupled with positive buzz from CES 2026, sharpens its competitive edge in a sector dominated by giants like Salesforce and Adobe.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
Atlassian confronts a mounting identity theft campaign targeting its systems while rival Anthropic launches a competing AI collaboration tool, adding pressure to a stock already down over 50% in the past year.
